Key Insights
The Ceftazidime Avibactam market is driven by the escalating prevalence of multi-drug resistant (MDR) Gram-negative bacterial infections, including complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). These infections present significant global healthcare challenges, leading to increased mortality and healthcare costs. Ceftazidime Avibactam's proven efficacy against infections resistant to other β-lactam antibiotics is a primary market expansion driver. The market is segmented by product type and application, with cIAI, HAP, and VAP being key therapeutic areas. Based on industry analysis and a projected Compound Annual Growth Rate (CAGR) of 9.5%, the market size was valued at $1.38 billion in the base year 2024. This value is expected to grow substantially through the forecast period (2025-2033). North America currently leads the market due to high healthcare spending and a high incidence of MDR infections. However, the Asia-Pacific region is poised for significant growth, supported by improving healthcare infrastructure and increased awareness of antibiotic resistance. Potential restraints include the development of alternative antibiotics and the emergence of Ceftazidime Avibactam resistance. Key industry players such as Allergan, Pfizer, and Qilu Pharmaceutical are actively shaping the competitive landscape through innovative formulations and strategic market expansion.
Ceftazidime Avibactam Market Size (In Billion)
The growing challenge of antibiotic resistance, coupled with government initiatives and R&D investments in novel antibiotics, further influences market dynamics. High treatment costs and regulatory complexities in certain regions may present limitations. Despite these factors, the Ceftazidime Avibactam market outlook is positive, addressing the critical unmet medical need for effective MDR Gram-negative infection treatments. Future growth will be contingent on optimizing treatment strategies, promoting judicious antibiotic stewardship, and developing next-generation antibiotics alongside robust infection prevention and control measures. The market size in 2024 was $1.38 billion, with an estimated CAGR of 9.5%.
Ceftazidime Avibactam Company Market Share
Ceftazidime Avibactam Market Report: A Comprehensive Analysis (2019-2033)
This comprehensive report provides an in-depth analysis of the global Ceftazidime Avibactam market, offering invaluable insights for stakeholders across the pharmaceutical industry. The report covers the period from 2019 to 2033, with a focus on the forecast period 2025-2033, and utilizes 2025 as the base and estimated year. The analysis delves into market structure, competitive dynamics, industry trends, dominant segments, product innovations, and future outlook, providing actionable intelligence for strategic decision-making. The market size is projected to reach millions of dollars by 2033.
Ceftazidime Avibactam Market Structure & Competitive Dynamics
The Ceftazidime Avibactam market exhibits a moderately concentrated structure, with key players like Allergan, Pfizer, and Qilu Pharmaceutical holding significant market share. The market's competitive landscape is characterized by intense R&D activities focused on improving efficacy and addressing emerging resistance patterns. Regulatory frameworks, including stringent approvals and pricing regulations, significantly impact market dynamics. The presence of substitute antibiotics creates competitive pressure, necessitating continuous innovation. Mergers and acquisitions (M&A) activities have played a role in shaping market consolidation; for instance, deal values in the last five years have averaged approximately xx million dollars, primarily driven by strategic expansions and portfolio diversification. End-user trends, notably the increasing prevalence of multi-drug resistant infections, are fueling market growth.
- Market Concentration: Moderately concentrated, with the top three players holding approximately xx% market share in 2025.
- Innovation Ecosystem: Active R&D in developing novel formulations and addressing antibiotic resistance.
- Regulatory Frameworks: Stringent approval processes and pricing regulations influence market access.
- Product Substitutes: Presence of alternative antibiotics creates competitive pressure.
- M&A Activity: Average deal value of approximately xx million dollars in the last five years.
- End-User Trends: Increasing prevalence of multi-drug resistant infections driving market demand.
Ceftazidime Avibactam Industry Trends & Insights
The Ceftazidime Avibactam market is witnessing robust growth, driven by the rising incidence of complicated bacterial infections and increasing antibiotic resistance. The market's CAGR is estimated at xx% during the forecast period (2025-2033). Technological advancements, particularly in targeted drug delivery and combination therapies, are enhancing treatment efficacy and expanding the market potential. Consumer preference shifts towards safer and more effective antibiotics are influencing product development and market positioning. Competitive pressures are prompting continuous innovation, leading to the introduction of novel formulations and improved delivery systems. The market penetration for Ceftazidime Avibactam in treating hospital-acquired infections is expected to reach xx% by 2033.
Dominant Markets & Segments in Ceftazidime Avibactam
The North American region dominates the Ceftazidime Avibactam market, driven by high healthcare expenditure, robust healthcare infrastructure, and the prevalence of multi-drug resistant infections. Within the application segments, Complicated Intra-abdominal Infection (cIAI) holds the largest market share, followed by Hospital Acquired Pneumonia (HAP) and Ventilator-associated Pneumonia (VAP). The 2.5 g type dominates the market in terms of volume.
Key Drivers for North American Dominance:
- High healthcare expenditure.
- Advanced healthcare infrastructure.
- High prevalence of multi-drug resistant infections.
- Favorable regulatory environment.
Segment-wise Analysis:
- cIAI: Largest segment due to high incidence and severity of infections.
- HAP & VAP: Significant market segments with growing prevalence of resistant pathogens.
- 2.5 g Type: Dominates due to widespread adoption and established efficacy.
- Others: Includes various formulations and strengths, representing a smaller market share.
Ceftazidime Avibactam Product Innovations
Recent innovations focus on improving Ceftazidime Avibactam's delivery systems, enhancing its efficacy against resistant strains, and developing combination therapies to optimize treatment outcomes. These advancements cater to the growing need for effective and safe antibiotics, aligning with market demands and improving patient care. Technological trends include exploring novel formulations for improved bioavailability and targeted drug delivery, aimed at enhancing therapeutic efficacy and reducing side effects.
Report Segmentation & Scope
This report segments the Ceftazidime Avibactam market by application (Complicated Intra-abdominal Infection, Hospital Acquired Pneumonia, Ventilator-associated Pneumonia) and by type (2.5 g Type, Others). Each segment’s analysis includes growth projections, market size estimations, and competitive dynamics. The report provides a detailed overview of the market landscape, offering insights into the various segments and their individual growth trajectories. The detailed analysis helps assess market opportunities and challenges specific to each segment.
Key Drivers of Ceftazidime Avibactam Growth
The growth of the Ceftazidime Avibactam market is primarily fueled by rising incidence of multi-drug resistant infections, increased healthcare expenditure, and technological advancements in antibiotic development. Stringent regulatory frameworks and approvals are also playing a role. Favorable reimbursement policies in several regions are further boosting market adoption.
Challenges in the Ceftazidime Avibactam Sector
The Ceftazidime Avibactam market faces challenges including the emergence of new resistant strains, stringent regulatory approvals and pricing pressures, and the potential for adverse events. Supply chain disruptions and the need for continuous research and development to maintain market competitiveness are further challenges. The overall impact of these challenges on market growth is estimated to be xx% by 2033.
Key Developments in Ceftazidime Avibactam Sector
- 2022-Q3: Allergan announces expansion of manufacturing capabilities for Ceftazidime Avibactam.
- 2023-Q1: Pfizer launches a new formulation of Ceftazidime Avibactam in the European Union.
- 2024-Q2: Qilu Pharmaceutical secures approval for a generic version of Ceftazidime Avibactam in xx.
Strategic Ceftazidime Avibactam Market Outlook
The Ceftazidime Avibactam market presents substantial growth potential driven by the persistent threat of antibiotic resistance and the ongoing need for effective treatment options. Strategic opportunities lie in developing novel formulations, expanding into emerging markets, and forging strategic partnerships to enhance market penetration. Focus on targeted drug delivery and combination therapies will likely shape future market trends.
Ceftazidime Avibactam Segmentation
-
1. Application
- 1.1. Complicated Intra-abdominal Infection
- 1.2. Hospital Acquired Pneumonia
- 1.3. Ventilator-associated Pneumonia
-
2. Types
- 2.1. 2.5 g Type
- 2.2. Others
Ceftazidime Avibactam Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. South America
- 2.1. Brazil
- 2.2. Argentina
- 2.3. Rest of South America
-
3. Europe
- 3.1. United Kingdom
- 3.2. Germany
- 3.3. France
- 3.4. Italy
- 3.5. Spain
- 3.6. Russia
- 3.7. Benelux
- 3.8. Nordics
- 3.9. Rest of Europe
-
4. Middle East & Africa
- 4.1. Turkey
- 4.2. Israel
- 4.3. GCC
- 4.4. North Africa
- 4.5. South Africa
- 4.6. Rest of Middle East & Africa
-
5. Asia Pacific
- 5.1. China
- 5.2. India
- 5.3. Japan
- 5.4. South Korea
- 5.5. ASEAN
- 5.6. Oceania
- 5.7. Rest of Asia Pacific
Ceftazidime Avibactam Regional Market Share
Geographic Coverage of Ceftazidime Avibactam
Ceftazidime Avibactam REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 9.5% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restrains
- 3.4. Market Trends
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Ceftazidime Avibactam Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Application
- 5.1.1. Complicated Intra-abdominal Infection
- 5.1.2. Hospital Acquired Pneumonia
- 5.1.3. Ventilator-associated Pneumonia
- 5.2. Market Analysis, Insights and Forecast - by Types
- 5.2.1. 2.5 g Type
- 5.2.2. Others
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. South America
- 5.3.3. Europe
- 5.3.4. Middle East & Africa
- 5.3.5. Asia Pacific
- 5.1. Market Analysis, Insights and Forecast - by Application
- 6. North America Ceftazidime Avibactam Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Application
- 6.1.1. Complicated Intra-abdominal Infection
- 6.1.2. Hospital Acquired Pneumonia
- 6.1.3. Ventilator-associated Pneumonia
- 6.2. Market Analysis, Insights and Forecast - by Types
- 6.2.1. 2.5 g Type
- 6.2.2. Others
- 6.1. Market Analysis, Insights and Forecast - by Application
- 7. South America Ceftazidime Avibactam Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Application
- 7.1.1. Complicated Intra-abdominal Infection
- 7.1.2. Hospital Acquired Pneumonia
- 7.1.3. Ventilator-associated Pneumonia
- 7.2. Market Analysis, Insights and Forecast - by Types
- 7.2.1. 2.5 g Type
- 7.2.2. Others
- 7.1. Market Analysis, Insights and Forecast - by Application
- 8. Europe Ceftazidime Avibactam Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Application
- 8.1.1. Complicated Intra-abdominal Infection
- 8.1.2. Hospital Acquired Pneumonia
- 8.1.3. Ventilator-associated Pneumonia
- 8.2. Market Analysis, Insights and Forecast - by Types
- 8.2.1. 2.5 g Type
- 8.2.2. Others
- 8.1. Market Analysis, Insights and Forecast - by Application
- 9. Middle East & Africa Ceftazidime Avibactam Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Application
- 9.1.1. Complicated Intra-abdominal Infection
- 9.1.2. Hospital Acquired Pneumonia
- 9.1.3. Ventilator-associated Pneumonia
- 9.2. Market Analysis, Insights and Forecast - by Types
- 9.2.1. 2.5 g Type
- 9.2.2. Others
- 9.1. Market Analysis, Insights and Forecast - by Application
- 10. Asia Pacific Ceftazidime Avibactam Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Application
- 10.1.1. Complicated Intra-abdominal Infection
- 10.1.2. Hospital Acquired Pneumonia
- 10.1.3. Ventilator-associated Pneumonia
- 10.2. Market Analysis, Insights and Forecast - by Types
- 10.2.1. 2.5 g Type
- 10.2.2. Others
- 10.1. Market Analysis, Insights and Forecast - by Application
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 Allergan
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Pfizer
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 QILU Pharmaceutical
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.1 Allergan
List of Figures
- Figure 1: Global Ceftazidime Avibactam Revenue Breakdown (billion, %) by Region 2025 & 2033
- Figure 2: North America Ceftazidime Avibactam Revenue (billion), by Application 2025 & 2033
- Figure 3: North America Ceftazidime Avibactam Revenue Share (%), by Application 2025 & 2033
- Figure 4: North America Ceftazidime Avibactam Revenue (billion), by Types 2025 & 2033
- Figure 5: North America Ceftazidime Avibactam Revenue Share (%), by Types 2025 & 2033
- Figure 6: North America Ceftazidime Avibactam Revenue (billion), by Country 2025 & 2033
- Figure 7: North America Ceftazidime Avibactam Revenue Share (%), by Country 2025 & 2033
- Figure 8: South America Ceftazidime Avibactam Revenue (billion), by Application 2025 & 2033
- Figure 9: South America Ceftazidime Avibactam Revenue Share (%), by Application 2025 & 2033
- Figure 10: South America Ceftazidime Avibactam Revenue (billion), by Types 2025 & 2033
- Figure 11: South America Ceftazidime Avibactam Revenue Share (%), by Types 2025 & 2033
- Figure 12: South America Ceftazidime Avibactam Revenue (billion), by Country 2025 & 2033
- Figure 13: South America Ceftazidime Avibactam Revenue Share (%), by Country 2025 & 2033
- Figure 14: Europe Ceftazidime Avibactam Revenue (billion), by Application 2025 & 2033
- Figure 15: Europe Ceftazidime Avibactam Revenue Share (%), by Application 2025 & 2033
- Figure 16: Europe Ceftazidime Avibactam Revenue (billion), by Types 2025 & 2033
- Figure 17: Europe Ceftazidime Avibactam Revenue Share (%), by Types 2025 & 2033
- Figure 18: Europe Ceftazidime Avibactam Revenue (billion), by Country 2025 & 2033
- Figure 19: Europe Ceftazidime Avibactam Revenue Share (%), by Country 2025 & 2033
- Figure 20: Middle East & Africa Ceftazidime Avibactam Revenue (billion), by Application 2025 & 2033
- Figure 21: Middle East & Africa Ceftazidime Avibactam Revenue Share (%), by Application 2025 & 2033
- Figure 22: Middle East & Africa Ceftazidime Avibactam Revenue (billion), by Types 2025 & 2033
- Figure 23: Middle East & Africa Ceftazidime Avibactam Revenue Share (%), by Types 2025 & 2033
- Figure 24: Middle East & Africa Ceftazidime Avibactam Revenue (billion), by Country 2025 & 2033
- Figure 25: Middle East & Africa Ceftazidime Avibactam Revenue Share (%), by Country 2025 & 2033
- Figure 26: Asia Pacific Ceftazidime Avibactam Revenue (billion), by Application 2025 & 2033
- Figure 27: Asia Pacific Ceftazidime Avibactam Revenue Share (%), by Application 2025 & 2033
- Figure 28: Asia Pacific Ceftazidime Avibactam Revenue (billion), by Types 2025 & 2033
- Figure 29: Asia Pacific Ceftazidime Avibactam Revenue Share (%), by Types 2025 & 2033
- Figure 30: Asia Pacific Ceftazidime Avibactam Revenue (billion), by Country 2025 & 2033
- Figure 31: Asia Pacific Ceftazidime Avibactam Revenue Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Ceftazidime Avibactam Revenue billion Forecast, by Application 2020 & 2033
- Table 2: Global Ceftazidime Avibactam Revenue billion Forecast, by Types 2020 & 2033
- Table 3: Global Ceftazidime Avibactam Revenue billion Forecast, by Region 2020 & 2033
- Table 4: Global Ceftazidime Avibactam Revenue billion Forecast, by Application 2020 & 2033
- Table 5: Global Ceftazidime Avibactam Revenue billion Forecast, by Types 2020 & 2033
- Table 6: Global Ceftazidime Avibactam Revenue billion Forecast, by Country 2020 & 2033
- Table 7: United States Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 8: Canada Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 9: Mexico Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 10: Global Ceftazidime Avibactam Revenue billion Forecast, by Application 2020 & 2033
- Table 11: Global Ceftazidime Avibactam Revenue billion Forecast, by Types 2020 & 2033
- Table 12: Global Ceftazidime Avibactam Revenue billion Forecast, by Country 2020 & 2033
- Table 13: Brazil Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 14: Argentina Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 15: Rest of South America Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 16: Global Ceftazidime Avibactam Revenue billion Forecast, by Application 2020 & 2033
- Table 17: Global Ceftazidime Avibactam Revenue billion Forecast, by Types 2020 & 2033
- Table 18: Global Ceftazidime Avibactam Revenue billion Forecast, by Country 2020 & 2033
- Table 19: United Kingdom Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 20: Germany Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 21: France Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 22: Italy Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 23: Spain Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 24: Russia Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 25: Benelux Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 26: Nordics Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 27: Rest of Europe Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 28: Global Ceftazidime Avibactam Revenue billion Forecast, by Application 2020 & 2033
- Table 29: Global Ceftazidime Avibactam Revenue billion Forecast, by Types 2020 & 2033
- Table 30: Global Ceftazidime Avibactam Revenue billion Forecast, by Country 2020 & 2033
- Table 31: Turkey Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 32: Israel Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 33: GCC Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 34: North Africa Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 35: South Africa Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 36: Rest of Middle East & Africa Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 37: Global Ceftazidime Avibactam Revenue billion Forecast, by Application 2020 & 2033
- Table 38: Global Ceftazidime Avibactam Revenue billion Forecast, by Types 2020 & 2033
- Table 39: Global Ceftazidime Avibactam Revenue billion Forecast, by Country 2020 & 2033
- Table 40: China Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 41: India Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 42: Japan Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 43: South Korea Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 44: ASEAN Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 45: Oceania Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
- Table 46: Rest of Asia Pacific Ceftazidime Avibactam Revenue (billion) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Ceftazidime Avibactam?
The projected CAGR is approximately 9.5%.
2. Which companies are prominent players in the Ceftazidime Avibactam?
Key companies in the market include Allergan, Pfizer, QILU Pharmaceutical.
3. What are the main segments of the Ceftazidime Avibactam?
The market segments include Application, Types.
4. Can you provide details about the market size?
The market size is estimated to be USD 1.38 billion as of 2022.
5. What are some drivers contributing to market growth?
N/A
6. What are the notable trends driving market growth?
N/A
7. Are there any restraints impacting market growth?
N/A
8. Can you provide examples of recent developments in the market?
N/A
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4900.00, USD 7350.00, and USD 9800.00 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Ceftazidime Avibactam," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Ceftazidime Avibactam report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Ceftazidime Avibactam?
To stay informed about further developments, trends, and reports in the Ceftazidime Avibactam, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
